Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Molecular Mechanisms and Pathophysiology of Cardiovascular Diseases
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Mechanisms and Pathophysiology of Cardiovascular Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 7449

Special Issue Editor

Prof. Dr. Ping-Yen Liu

E-Mail Website
Guest Editor
Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70457, Taiwan
Interests: cardiovascular disease; ageing heart; animal echocardiography; cardiovascular medicine research; onco-cardiology

Special Issue Information

Dear Colleagues,

In recent years, the incidence of cardiovascular disease has continued to rise, and the age of onset has also advanced. Cardiovascular disease has become an important problem for human health, and therefore it is imperative to strengthen the prevention and treatment of cardiovascular diseases. However, their pathogenesis still remains unclear.

This research topic aims to find a solution to unsolved problems in the field of cardiovascular disease research, including drug therapy; gene therapy; vascular interventional therapy; immune cell (cardiomyocyte, vascular endothelial cell) function; hypertension, multi-omics analysis, etc.

This Special Issue “Frontiers in the Cardiovascular Diseases” welcomes original research articles, reviews, methods, and other article types focused on (but not limited to) the following areas:

  1. The etiology and treatment of cardiovascular disease.
  2. The role of immune cells in cardiovascular disease.
  3. Advanced diagnostic tools and research methods for cardiovascular disease.

Prof. Dr. Ping-Yen Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular disease
  • cardiomyocyte
  • vascular endothelial cell
  • drug therapy
  • multi-omics analysis

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 1055 KiB  
Review
Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option
by Alessandro Maloberti, Saverio Fabbri, Valentina Colombo, Elena Gualini, Massimiliano Monticelli, Francesca Daus, Andrea Busti, Michele Galasso, Lorenzo De Censi, Michela Algeri, Piera Angelica Merlini and Cristina Giannattasio
Int. J. Mol. Sci. 2023, 24(1), 170; https://doi.org/10.3390/ijms24010170 - 22 Dec 2022
Cited by 8 | Viewed by 2522
Abstract
Atherosclerosis is a chronic and progressive inflammatory process beginning early in life with late clinical manifestation. This slow pathological trend underlines the importance to early identify high-risk patients and to treat intensively risk factors to prevent the onset and/or the progression of atherosclerotic [...] Read more.
Atherosclerosis is a chronic and progressive inflammatory process beginning early in life with late clinical manifestation. This slow pathological trend underlines the importance to early identify high-risk patients and to treat intensively risk factors to prevent the onset and/or the progression of atherosclerotic lesions. In addition to the common Cardiovascular (CV) risk factors, new markers able to increase the risk of CV disease have been identified. Among them, high levels of Lipoprotein(a)—Lp(a)—lead to very high risk of future CV diseases; this relationship has been well demonstrated in epidemiological, mendelian randomization and genome-wide association studies as well as in meta-analyses. Recently, new aspects have been identified, such as its association with aortic stenosis. Although till recent years it has been considered an unmodifiable risk factor, specific drugs have been developed with a strong efficacy in reducing the circulating levels of Lp(a) and their capacity to reduce subsequent CV events is under testing in ongoing trials. In this paper we will review all these aspects: from the synthesis, clearance and measurement of Lp(a), through the findings that examine its association with CV diseases and aortic stenosis to the new therapeutic options that will be available in the next years. Full article
(This article belongs to the Special Issue Molecular Mechanisms and Pathophysiology of Cardiovascular Diseases)
►▼ Show Figures

Figure 1

15 pages, 823 KiB  
Review
Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease
by Qingyu Wu and Shenghan Chen
Int. J. Mol. Sci. 2022, 23(21), 13429; https://doi.org/10.3390/ijms232113429 - 3 Nov 2022
Cited by 1 | Viewed by 2064
Abstract
Proprotein convertase subtilisin/kexin 6 (PCSK6) is a secreted serine protease expressed in most major organs, where it cleaves a wide range of growth factors, signaling molecules, peptide hormones, proteolytic enzymes, and adhesion proteins. Studies in Pcsk6-deficient mice have demonstrated the importance of [...] Read more.
Proprotein convertase subtilisin/kexin 6 (PCSK6) is a secreted serine protease expressed in most major organs, where it cleaves a wide range of growth factors, signaling molecules, peptide hormones, proteolytic enzymes, and adhesion proteins. Studies in Pcsk6-deficient mice have demonstrated the importance of Pcsk6 in embryonic development, body axis specification, ovarian function, and extracellular matrix remodeling in articular cartilage. In the cardiovascular system, PCSK6 acts as a key modulator in heart formation, lipoprotein metabolism, body fluid homeostasis, cardiac repair, and vascular remodeling. To date, dysregulated PCSK6 expression or function has been implicated in major cardiovascular diseases, including atrial septal defects, hypertension, atherosclerosis, myocardial infarction, and cardiac aging. In this review, we describe biochemical characteristics and posttranslational modifications of PCSK6. Moreover, we discuss the role of PCSK6 and related molecular mechanisms in cardiovascular biology and disease. Full article
(This article belongs to the Special Issue Molecular Mechanisms and Pathophysiology of Cardiovascular Diseases)
►▼ Show Figures

Figure 1

24 pages, 1490 KiB  
Review
Deciphering the Basis of Molecular Biology of Selected Cardiovascular Diseases: A View on Network Medicine
by Noora Alhajri, Mohammad Rustom, Adedayo Adegbile, Weshah Ahmed, Salsabeel Kilidar and Nariman Afify
Int. J. Mol. Sci. 2022, 23(19), 11421; https://doi.org/10.3390/ijms231911421 - 28 Sep 2022
Cited by 2 | Viewed by 1907
Abstract
Cardiovascular diseases are the leading cause of death across the world. For decades, researchers have been studying the causes of cardiovascular disease, yet many of them remain undiscovered or poorly understood. Network medicine is a recently expanding, integrative field that attempts to elucidate [...] Read more.
Cardiovascular diseases are the leading cause of death across the world. For decades, researchers have been studying the causes of cardiovascular disease, yet many of them remain undiscovered or poorly understood. Network medicine is a recently expanding, integrative field that attempts to elucidate this issue by conceiving of disease as the result of disruptive links between multiple interconnected biological components. Still in its nascent stages, this revolutionary application of network science facilitated a number of important discoveries in complex disease mechanisms. As methodologies become more advanced, network medicine harbors the potential to expound on the molecular and genetic complexities of disease to differentiate how these intricacies govern disease manifestations, prognosis, and therapy. This is of paramount importance for confronting the incredible challenges of current and future cardiovascular disease research. In this review, we summarize the principal molecular and genetic mechanisms of common cardiac pathophysiologies as well as discuss the existing knowledge on therapeutic strategies to prevent, halt, or reverse these pathologies. Full article
(This article belongs to the Special Issue Molecular Mechanisms and Pathophysiology of Cardiovascular Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop